{"organizations": [], "uuid": "ef7e1856c5857230ec805d749c38f1648cc114e6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-rhythm-pharmaceuticals-announces-p/brief-rhythm-pharmaceuticals-announces-progress-in-clinical-development-of-setmelanotide-idUSFWN1OZ0N8", "country": "US", "domain_rank": 408, "title": "BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T19:44:00.000+02:00", "replies_count": 0, "uuid": "ef7e1856c5857230ec805d749c38f1648cc114e6"}, "author": "", "url": "https://www.reuters.com/article/brief-rhythm-pharmaceuticals-announces-p/brief-rhythm-pharmaceuticals-announces-progress-in-clinical-development-of-setmelanotide-idUSFWN1OZ0N8", "ord_in_thread": 0, "title": "BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide", "locations": [], "entities": {"persons": [{"name": "setmelanotide", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - rhythm pharmaceuticals inc", "sentiment": "none"}, {"name": "development of setmelanotide reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 5:44 PM / in 6 minutes BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide Reuters Staff 1 Min Read \nJan 4 (Reuters) - Rhythm Pharmaceuticals Inc: \n* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY \n* RHYTHM PHARMACEUTICALS - SETMELANOTIDE GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY \n* RHYTHM PHARMACEUTICALS - FINALIZED PROTOCOL FOR PIVOTAL PHASE 3 CLINICAL TRIAL IN PRO-OPIOMELANOCORTIN (POMC) DEFICIENCY OBESITY \n* RHYTHM PHARMACEUTICALS - CONFIRMS PLANS TO FILE NDA WITH FDA BASED ON ONE-YEAR DATA FROM 10 PATIENT COHORT IN POMC PHASE 3 CLINICAL TRIAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T19:44:00.000+02:00", "crawled": "2018-01-04T20:06:19.003+02:00", "highlightTitle": ""}